Related references
Note: Only part of the references are listed.Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds
Nieves Martinez-Peinado et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against Trypanosoma cruzi
Gustavo Benaim et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
Rob W. van der Pluijm et al.
LANCET (2020)
Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
Nieves Martinez-Peinado et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity
Nieves Martinez-Peinado et al.
PARASITES & VECTORS (2020)
Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
Julio Alonso-Padilla et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2019)
Flecainide: Electrophysiological properties, clinical indications, and practical aspects
Enrico Paolini et al.
PHARMACOLOGICAL RESEARCH (2019)
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing
Susana Santos Braga
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
The senseless orphanage of Chagas disease
Cristina Alonso-Vega et al.
EXPERT OPINION ON ORPHAN DRUGS (2019)
Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection
Caio Haddad Franco et al.
TROPICAL MEDICINE AND INFECTIOUS DISEASE (2019)
Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis
Clara Crespillo-Andujar et al.
DRUG SAFETY (2018)
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial
Faustino Torrico et al.
LANCET INFECTIOUS DISEASES (2018)
Isosorbide and nifedipine for Chagas' megaesophagus: A systematic review and meta-analysis
Celina Borges Migliavaca et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study
Daiane Dias Ferreira et al.
JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES (2018)
Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most
Temmy Sunyoto et al.
BMJ GLOBAL HEALTH (2018)
Assessing drug efficacy against Plasmodium falciparum liver stages in vivo
Erika L. Flannery et al.
JCI INSIGHT (2018)
Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca2+ Channel
Andrea K. Pinto-Martinez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Biological factors that impinge on Chagas disease drug development
Amanda F. Francisco et al.
PARASITOLOGY (2017)
Artemisinin and its derivatives in treating protozoan infections beyond malaria
Cecilia Shi Ni Loo et al.
PHARMACOLOGICAL RESEARCH (2017)
Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy
M. R. Simoes-Silva et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum
Vanessa Ribeiro Moreira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy
Michael D. Lewis et al.
CELLULAR MICROBIOLOGY (2016)
Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
Colin J. Forsyth et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target
Veronica Seguel et al.
EXPERIMENTAL PARASITOLOGY (2016)
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare et al.
NATURE (2016)
A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases
Ariel Jose Berenstein et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
Manu De Rycker et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Defibrotide (Defitelio): A New Addition to the Stockpile of Food and Drug Administration-approved Oligonucleotide Drugs
C. Y. Stein et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi
Arlete Rita Penitente et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2015)
New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource
Imanol Pena et al.
SCIENTIFIC REPORTS (2015)
Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line
Julio Alonso-Padilla et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Pentoxifylline Reverses Chronic Experimental Chagasic Cardiomyopathy in Association with Repositioning of Abnormal CD8+ T-Cell Response
Isabela Resende Pereira et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics
Jong Min Choi et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning
Marcel Kaiser et al.
PLOS ONE (2015)
A New Experimental Model for Assessing Drug Efficacy against Trypanosoma cruzi Infection Based on Highly Sensitive In Vivo Imaging
Michael D. Lewis et al.
JOURNAL OF BIOMOLECULAR SCREENING (2015)
Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruzi
Maria V. Diaz et al.
ACTA TROPICA (2014)
Susceptibilidad in vitro a hexadecilfosfocolina (miltefosina), nifurtimox y benznidazole de cepas de Trypanosoma cruzi aisladas en Santander, Colombia
Patricia Escobar et al.
Biomedica (2014)
Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Israel Molina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
In vitro investigation of the efficacy of novel diamidines against Trypanosoma cruzi
B. L. Timm et al.
PARASITOLOGY (2014)
Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials
Gijs W. D. Landman et al.
PLOS ONE (2014)
Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
Joseph D. Planer et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria
Jane Achan et al.
MALARIA JOURNAL (2011)
Genetic Reconstruction of Protozoan rRNA Decoding Sites Provides a Rationale for Paromomycin Activity against Leishmania and Trypanosoma
Sven N. Hobbie et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening
Grasiella Andriani et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Chagas disease in Spain, the United States and other non-endemic countries
Joaquim Gascon et al.
ACTA TROPICA (2010)
Tolerance of Benznidazole in Treatment of Chagas' Disease in Adults
Maria-Jesus Pinazo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study
Juliana Q. Reimao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Tolerance and Safety of Nifurtimox in Patients with Chronic Chagas Disease
Yves Jackson et al.
CLINICAL INFECTIOUS DISEASES (2010)
NEW INSIGHTS IN CHAGAS' DISEASE TREATMENT
J. A. Urbina
DRUGS OF THE FUTURE (2010)
Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library Screening
Esther Bettiol et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
Importance of TNF-α in the course of acute infection with Trypanosoma cruzi:: influence of its inhibition by pentoxifylline treatment
Sonia G. Andrade et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2008)
CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]
Franklin R. Quiros et al.
TRIALS (2006)
Ticks, ivermectin, and experimental Chagas disease
JCP Dias et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2005)
Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection
AP De Souza et al.
PARASITOLOGY RESEARCH (2004)
Acidocalcisomes and the contractile vacuole complex are involved in osmoregulation in Trypanosoma cruzi
P Rohloff et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol
LR Leite et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2003)
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi
VB Saraiva et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi
RM Santa-Rita et al.
ACTA TROPICA (2000)
Share Paper
